Related Experiment Video
Updated: Jun 1, 2026
10:19
Substernal Thyroid Biopsy Using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration
Published on: November 10, 2014
Thyroid Artery Embolization for Benign Symptomatic Multinodular Euthyroid Goiter: 24-Month Outcomes from a
Fahrettin Kucukay1, Huseyin Saygin Tuna2
1Department of Interventional Radiology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
Summary
Thyroid artery embolization (TAE) significantly reduced goiter volume and improved symptoms in patients with benign multinodular goiter. This minimally invasive procedure offers sustained results with low reintervention rates.
Area of Science:
- Interventional Radiology
- Endocrinology
- Vascular Medicine
Background:
- Benign symptomatic multinodular goiter poses a significant clinical challenge.
- Current treatment options may involve surgery with associated risks.
- Minimally invasive alternatives are sought for goiter management.
Purpose of the Study:
- To assess the efficacy of thyroid artery embolization (TAE) for benign symptomatic multinodular euthyroid goiter.
- To evaluate volumetric changes and clinical outcomes following TAE.
- To determine recurrence and complication rates associated with TAE.
Main Methods:
- Retrospective single-center observational study (December 2021 - June 2024).
- Analysis of 40 consecutive patients undergoing TAE.
- Primary endpoints: percentage change in total thyroid and dominant nodule volume at 12 and 24 months.
Main Results:
- Significant volume reduction: total thyroid volume decreased by ~60%, dominant nodule volume by ~68% at 24 months (p < .001).
- High symptom resolution rates: 95% at 12 months, 97.5% at 24 months.
- Low recurrence (2.5%) and reintervention (7.5%) rates; 35% overall complication rate, with 5% major complications.
Conclusions:
- TAE is an effective treatment for benign symptomatic multinodular goiter.
- Achieves substantial and sustained thyroid volume reduction.
- Offers high rates of clinical improvement and favorable mid-term safety profile.
Related Concept Videos
01:27Goiter
Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...